skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.06d (Release date: 2017-06-26)
SearchBox Top
SearchBox Bottom
Gag:267-274 Peptide Vaccine (Code C102982)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Gag:267-274 Peptide Vaccine

Definition: A peptide vaccine containing the amino acids 267 through 274 of the human immunodeficiency virus type 1 (HIV-1) gag core protein (gag:267-274), with potential immunostimulating activity. Upon vaccination, the immune system may exert a potent cytotoxic T-lymphocyte (CTL) response against the xenoantigen gag:267-274 and produces pro-inflammatory cytokines. The concomitant administration of a cancer peptide vaccine may benefit from an already activated immune system and may augment an immune response against the administered tumor associated antigen(s). Gag:267-274 peptide is highly immunogenic and may potentially be used as a cancer immunoadjuvant.

Display Name: Gag:267-274 Peptide Vaccine

Label: Gag:267-274 Peptide Vaccine

NCI Thesaurus Code: C102982 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: CL437219  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
Gag:267-274 Peptide Vaccine

External Source Codes: 
PDQ Closed Trial Search ID 739970
PDQ Open Trial Search ID 739970 (check for NCI PDQ open clinical trial info)

Other Properties:
     Name Value (qualifiers indented underneath)
code C102982
Contributing_Source CTRP
Semantic_Type Immunologic Factor
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom